USA flag logo/image

An Official Website of the United States Government

Scale Up of Hyperpolarized Xe Production

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85818
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
HL087550
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
XEMED, LLC
16 Strafford Avenue DURHAM, NH -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: Scale Up of Hyperpolarized Xe Production
Agency: HHS
Contract: 1R43HL087550-01
Award Amount: $104,747.00
 

Abstract:

DESCRIPTION (provided by applicant): Hyperpolarized xenon MRI has been demonstrated to have exquisite sensitivity in functional imaging of lungs, likely the most technically promising and commercially viable technique. Production of high quality hyperpolar ized xenon has proven challenging. Three years ago our group at the University of New Hampshire identified an efficient method for polarization and developed an apparatus to exploit this regime, advancing the productivity of polarizers by more than one ord er of magnitude. Since that time, our efforts to further increase output by increasing laser power have not met with success. We have determined that laser heating of the gas leads to lower efficiency of the polarizer. We have invented a new apparatus that could essentially eliminate this barrier, allowing further scaling up of the polarized xenon output of our polarizer. We propose to implement this new invention and demonstrate an increase in polarization output of a factor of twenty over our existing pol arizer. A polarizer with this output, roughly one liter per minute, will be able to meet the research and clinical requirements of real-time pulmonary functional imaging protocols. Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death in the US. Hyperpolarized xenon MRI offers a highly quantitative and practical method for measuring functional parameters of lungs and tracking them over time, which would be a benefit for these patients, not only as a personal diagnostic agent, but also as a tool in the search for safe and effective inhaled therapeutic pharmaceuticals. In this proposal, the leading hyperpolarized xenon research group proposes to implement new technology that can scale up the output of our polarizer by another factor of twenty or more, achieving the goal of liter-per-minute production.

Principal Investigator:

Jan H. Distelbrink
6038681888
JAND@PHYSICS.UNH.EDU

Business Contact:

William Hersman
hersman@xemed.com
Small Business Information at Submission:

XEMED, LLC
XEMED, LLC 16 Strafford Avenue DURHAM, NH 03824

EIN/Tax ID: 201331118
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No